EU IVDR IVD Definition and Scope under Article 2(2)

1. Key takeaways

Whether a product is an IVD is determined by the three-part test in Article 2(2): form (reagents, calibrators, control materials, kits, instruments, apparatus, software or systems), purpose (intended by the manufacturer for the in vitro examination of specimens derived from the human body), and objective (one of six listed information purposes). A specimen receptacle is treated as an IVD directly under the final sentence of Article 2(2), without any further purpose-based argument.

The decisive evidence is always the manufacturer’s intended use as expressed in the instructions for use, the label and the marketing claims, not the underlying technology. Software and systems are expressly included in the definition, accessories, calibrators and control materials follow their own classification rules, and self-tests and near-patient tests are two separate definitions with different classification consequences. Getting the qualification decision right at the start prevents cascading errors in classification, conformity assessment and documentation.

2. Legal basis

The table below lists the provisions and guidance used to determine whether a product falls within the IVDR definition of an IVD.

MDCG 2019-11 is referenced here because software qualification disputes are the most frequent borderline cases in practice. The guidance is interpretative, so the binding text remains Article 2(2) read together with Annex VIII implementation rule 1.4.

3. Expert insights

Insight 1: the definition turns on the manufacturer’s intended use, not on technical principle.

Article 2(2) uses the wording intended by the manufacturer to be used in vitro for the examination of specimens derived from the human body. The same nucleic acid extraction instrument is an IVD if its instructions for use state that it is used to examine human specimens; if it is declared for research use only or for veterinary purposes, it falls outside the IVDR. The evidence for the qualification decision is therefore documentary: instructions for use, labels, claims and marketing materials. Teams that qualify products by technical similarity to known IVDs, rather than by intended use as documented, create files that notified bodies can challenge line by line.

Insight 2: software and systems are expressly listed in the definition.

Article 2(2) names software and systems in its list of forms, and Annex VIII implementation rule 1.4 completes the picture: software that drives or influences a device is classified with that device, while standalone software is classified according to its own intended purpose. As a result, there is no space in the IVDR for the argument that IVD software without corresponding hardware is not a device. Qualification records for software products should cite implementation rule 1.4 directly and describe the software’s intended purpose in the same terms used in the instructions for use.

Insight 3: accessories, calibrators and control materials each follow dedicated rules.

Article 2(4) defines the IVD accessory, and Annex VIII implementation rule 1.3 requires accessories to be classified separately. Implementation rules 1.5 and 1.6 provide that calibrators and control materials with assigned quantitative or qualitative values are classified with the device they are intended for. Rule 7 provides that control materials without assigned values are Class B. Together these rules mean that consumables sold on the same platform can sit in different risk classes, so procurement and regulatory teams must track them as separate entries rather than bundling them into one device record.

Insight 4: self-testing and near-patient testing are two independent definitions with different classification outcomes.

Under Article 2(5), a device for self-testing is intended for use by lay persons, including testing services provided to lay persons through information society services. Article 2(6) defines a device for near-patient testing as one that is not a self-test but is intended for use by healthcare professionals outside a laboratory, near the patient. Annex VIII rule 4 treats them separately: self-tests are in principle Class C, with pregnancy, fertility, cholesterol and urine glucose, urine red and white blood cells, and urine bacteria as Class B exceptions, while near-patient devices are classified on their own merits. Marketing channels that blur the two categories create misclassification risk.

4. Practical recommendations

1. Create a qualification decision record: work through the three-part test of Article 2(2) item by item, attaching the documentary evidence of the manufacturer’s intended use.
2. Issue a separate decision record for software products, citing Annex VIII implementation rule 1.4 and the software’s own intended purpose.
3. File specimen receptacles, accessories, calibrators and control materials as separate records, avoiding the mistake of merging them with the main instrument into one device entry.
4. Where a product serves several intended purposes simultaneously, apply implementation rules 1.8 and 1.9 and take the higher class.
5. For borderline products such as companion diagnostics and genetic tests, discuss the classification basis with the notified body early; disputed cases are referred under Article 47(2) to the competent authority of the Member State in which the manufacturer is registered.

5. Verification checklist

• □ Qualification decision completed under the three-part test of Article 2(2), with evidence retained
• □ Determined whether the product is a specimen receptacle (Article 2(3) / final sentence of Article 2(2))
• □ Determined whether the product is a self-test (Article 2(5)) or a near-patient test (Article 2(6))
• □ Software products handled under Annex VIII implementation rule 1.4
• □ Accessories, calibrators and control materials filed separately under implementation rules 1.3, 1.5, 1.6 and rule 7
• □ Multiple intended purposes resolved under implementation rules 1.8 and 1.9 by taking the higher class

Regulatory information verified as of 29 October 2026.

GRZAN helps manufacturers resolve IVD qualification and classification questions at the start of the EU IVDR compliance journey, including borderline and software products, kit structures and specimen receptacles, and prepares the documentation that notified bodies expect to see. For tailored compliance support on the EU IVDR market, contact info@grzanglobal.com.